In recent years, with the rapid advancement of precision medicine and biotechnology, nucleic acid therapeutics have become one of the most dynamic fields in global innovative drug development. From antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), to circular RNA (circRNA) and aptamers, nucleic acid drugs are continuously breaking through traditional treatment paradigms, demonstrating broad application prospects in rare diseases, oncology, infectious diseases, and metabolic disorders.
Unlike conventional small-molecule drugs, nucleic acid therapeutics require not only high-purity active pharmaceutical ingredients but also rely on advanced delivery systems and complex formulation processes. Therefore, establishing an efficient, stable, and comprehensive analytical testing system—from raw material development and process development to quality control—has become a critical enabler for the nucleic acid drug industry.
As a domestic enterprise specializing in the R&D of high-end charged aerosol detectors (CAD), Instrumax continues to deepen its expertise in universal detection technologies, providing end-to-end analytical testing solutions for nucleic acid drug research and production.
Rapid Growth in the Nucleic Acid Drug Industry Drives Continuous Upgrades in Analytical Testing Requirements
In recent years, nucleic acid therapeutics have emerged as a key growth driver in the global biopharmaceutical industry. As technology platforms such as ASO, siRNA, and mRNA mature, an increasing number of innovative drugs are advancing into clinical studies and commercialization, imposing higher demands on analytical testing technologies.
Nucleic acid drug development encompasses multiple stages, including oligonucleotide synthesis, purification, chemical modification, delivery system construction, formulation development, and quality control, each requiring accurate and reliable analytical data as a foundation.
The analytical scope includes not only:
- Oligonucleotide Active Pharmaceutical Ingredients (APIs)
- Synthetic Intermediates
- Truncated Sequences and Process-Related Impurities
- Degradation Products
- Buffer Salts and Inorganic Ions
but also the rapidly evolving nucleic acid delivery systems—Lipid Nanoparticles (LNP).
LNP delivery systems have become a critical component of the nucleic acid drug industry.
The maturation of LNP technology has enabled clinical breakthroughs for mRNA vaccines and siRNA therapeutics, establishing it as a key direction in current nucleic acid drug development.
Typical LNPs are composed of four classes of lipids:
- Ionizable Lipid
- Cholesterol
- Helper Phospholipids (e.g., DSPC)
- PEGylated Lipids (PEG-Lipid)
These lipid components determine the encapsulation efficiency, particle size distribution, stability, in vivo delivery efficiency, and drug safety of LNPs, representing Critical Quality Attributes (CQAs) that must be closely monitored during research, development, and manufacturing.
Therefore, accurate analysis of various lipid species and their ratios, along with the monitoring of impurities and degradation products, constitutes a vital aspect of nucleic acid drug quality control.
CAD Detectors Enable Quality Analysis of Nucleic Acid Drugs and LNPs
The CAD (Charged Aerosol Detector) independently developed by Instrumax employs advanced aerosol charging detection technology. It provides robust response for the vast majority of non-volatile compounds, independent of UV absorbance properties, making it particularly suitable for the analysis of nucleic acid drugs and lipid excipients.
During nucleic acid drug development, CAD can be widely applied to:
Nucleic Acid Drug Analysis
- Oligonucleotide Purity Analysis
- Detection of Synthesis Byproducts
- Process Impurity Analysis
- Evaluation of Chemical Modification Efficiency
- Stability Studies
- HPLC Method Development
- QC Quality Control
LNP Lipid Analysis
- Ionizable Lipid Quantitative Analysis
- Cholesterol Content Determination
- DSPC Analysis
- PEG-Lipid Quantitative Analysis
- LNP Lipid Ratio Monitoring
- Lipid Degradation Product Analysis
PEG and Excipient Analysis
PEGylated lipids are a critical component of current LNP systems, enhancing particle stability, extending in vivo circulation time, and improving delivery efficiency.
Due to the lack of significant UV absorption in PEG and most PEGylated lipids, traditional UV detection has certain limitations. In contrast, the charged aerosol detector (CAD) enables stable detection without reliance on chromophores and is widely applicable to:
- PEG-Lipid Quality Control
- PEG Raw Material Analysis
- PEG Residual Detection
- PEGylated Lipid Impurity Analysis
- Formulation Excipient Analysis
From raw materials to finished products, CAD covers the full lifecycle analysis of nucleic acid drugs.
Covering multiple critical analytical stages in nucleic acid drug R&D and production, Instrumax CAD detectors provide comprehensive solutions.
| Application Stage | Typical Analytes |
| Raw Material R&D | Oligonucleotides, nucleotide raw materials, modified monomers |
| Process Development | Intermediates, by-products, process-related impurities |
| Purification Process | Salt ions, buffer residuals |
| LNP Preparation | Ionizable Lipids, DSPC, Cholesterol, PEG-Lipid |
| Formulation Development | Excipients, Stabilizers, Lipid Ratios |
| Stability Studies | Degradation Products, Oxidation Products |
| QC Release | Raw Materials, Excipients, and Formulation Quality Control |
With advantages such as universal response, high sensitivity, excellent repeatability, and a wide linear range, the charged aerosol detector (CAD) complements UV detection to deliver more comprehensive analytical data for nucleic acid drug development.
Domestically innovated detection technology serving the future of the nucleic acid drug industry.
As the global nucleic acid drug industry advances rapidly, high-performance analytical instrumentation has become essential infrastructure for innovative drug R&D. As a domestic brand of high-end analytical instruments, Instrumax remains committed to independent innovation, continuously advancing charged aerosol detector (CAD) technology and expanding its applications in nucleic acid drugs, peptide drugs, biologics, natural products, and advanced formulations.
In the future, Instrumax will continue to collaborate with research institutes, biotechnology companies, CROs/CDMOs, and pharmaceutical enterprises to develop analytical and detection solutions covering R&D, process development, and quality control, leveraging domestic innovative technology to propel the nucleic acid drug industry toward higher-quality development.
Instrumax – The Eyes That Venture into the Unknown.